What Is the Optimal Setting for T-DXd in Early Breast Cancer? Experts Differ - Summary - MDSpire
Feature

What Is the Optimal Setting for T-DXd in Early Breast Cancer? Experts Differ

Trastuzumab deruxtecan (T-DXd) has claimed a large share of the HER2-positive breast cancer landscape, even finding room among tumors previously thought to be HER2-negative. The DESTINY series of tria...

Share

Trastuzumab deruxtecan (T-DXd) is rapidly becoming a key player in treating HER2-positive breast cancer, with trials like DESTINY-Breast051 and DESTINY-Breast112 examining its effectiveness in both adjuvant and neoadjuvant settings. A debate at the 43rd Annual Miami Breast Cancer Conference featured experts Dr. Paolo Tarantino and Dr. Giuseppe Curigliano, who presented opposing views on the optimal use of T-DXd. Tarantino advocates for neoadjuvant use to achieve higher pathologic complete response rates, while Curigliano supports adjuvant use based on long-term benefits demonstrated in trials.

Original Source(s)

What Is the Optimal Setting for T-DXd in Early Breast Cancer? Experts Differ

  • by Caroline Helwick

  • April 30, 2026

Related Content

Belzutifan/Lenvatinib Outperforms Cabozantinib After Checkpoint Inhibitors in Advanced Renal Cell Carcinoma

At the first and second interim analyses of the phase III LITESPARK-011 trial, treatment with the novel first-in-class hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor belzutifan plus lenvatinib im...

Acupuncture for Nocturia in Survivors of Prostate Cancer

Guest Editor’s Note: Nocturia, waking up from sleep more than once to urinate, is prevalent in survivors of prostate cancer and is associated with a diminished quality of life and a higher mortality t...

Accelerating Biopharmaceutical Development with CE-MS

Microfluidic CE-MS interfaces simplifies and streamlines biotherapeutic characterization to reduce turnaround times in bioanalytical labs

  • April 30, 2026

  • 7 min